OsteoSight Hip
Overview
OsteoSight™ is an AI-driven software developed by Naitive Technologies to transform orthopedic care by enabling the opportunistic assessment of bone mineral density (BMD) from routine X-rays. It is specifically designed to analyze standard anteroposterior (AP) radiographs of the hip or pelvis in patients aged 50 years and older. The tool identifies cases at risk for low BMD, which is a key indicator of osteoporosis, a condition often undiagnosed until a fracture occurs.
By seamlessly integrating into existing orthopedic and radiology workflows, OsteoSight™ provides a notification in the form of a report to aid interpreting physicians in identifying patients with possible low BMD at the femoral neck. This early identification prompts a clinical assessment of bone health, supporting earlier interventions, improved surgical planning, and ultimately enhancing patient outcomes. The technology has received FDA 510(k) clearance (K251408) and was designated an FDA Breakthrough Device in 2023, with its diagnostic accuracy, reproducibility, and robustness validated in peer-reviewed research. OsteoSight™ aims to address the urgent unmet clinical need in osteoporosis management, allowing orthopedic practices to take a proactive role and potentially expand their services.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Opportunistic assessment of bone mineral density (BMD) from routine X-rays
- Analyzes hip or pelvis X-rays in patients 50 years and older
- Identifies cases at risk for low BMD
- Provides a notification/report to aid interpreting physician
- Integrates into existing orthopedic and radiology workflows
- Validated in peer-reviewed research for diagnostic accuracy and reproducibility
- AI-driven software for musculoskeletal health
- Aids in earlier diagnosis and intervention for osteoporosis
- Excludes unsuitable cases including incorrect body parts, metalwork, and unacceptable femur positioning
Use Cases
- Early identification of patients at risk for osteoporosis
- Opportunistic bone health assessment during routine X-rays for other clinical concerns
- Streamlining referrals for comprehensive bone health assessment
- Supporting earlier interventions and improved surgical planning
- Expanding services and capturing ancillary revenue for orthopedic practices
- Improving patient outcomes by reducing osteoporotic fractures
What Physicians Need to Know
OsteoSight™ Hip is an opportunistic assessment tool that can help identify patients at risk of low bone mineral density from routine hip and pelvic X-rays, especially when DXA is not readily available or recently performed. The tool provides a report to alert physicians about potential low BMD, prompting further clinical evaluation and a comprehensive fracture risk assessment. It is important to remember that OsteoSight™ is not intended to replace DXA and does not diagnose osteopenia or osteoporosis. Physicians should continue to follow recommended practices for screening and assessment, even in the absence of an OsteoSight™ report.
OsteoSight™ operates as an AI-enabled software as a Medical Device (SaMD) that integrates with a host integration platform. This platform facilitates the secure transfer of DICOM images and associated metadata from clinical imaging systems. The software can be installed in the cloud, potentially within the existing secured network of a clinical site, and consists of microservices deployed through container orchestration services like Docker. The generated reports can be sent back to the PACS for physician interpretation.
Details
| Category | Clinical Decision Support & Reference, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Cloud-based, with integration capabilities for clinical imaging systems (e.g., PACS) for secure DICOM image transfer. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Cleared AI-estimated Naitive® Receives FDA 510(k) Clearance for OsteoSight™, AI-Enabled Opportunistic Bone Health Assessment. OsteoSight™ Receives FDA Breakthrough Device Designation. |
| Integrations | |
| EHR | Not specified |
| Specialties | Endocrinology, Orthopedics, Radiology |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2025-09-02 | K251408 510(k) | OsteoSight Hip |
What the Web Says
OsteoSight Hip (v1) by Naitive Technologies Ltd. is a medical device that received 510(k) clearance from the FDA on September 2, 2025. It was also part of the FDA's Breakthrough Devices Program, which aims to expedite the development and review of medical devices to provide timely access to patients and healthcare providers. As of the current date, detailed reviews and opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra are not readily available in the search results.
Overall: MixedLimitations
No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.
Based on reviews from: fda.gov, nyquistai.com
Last updated: 2026-10-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate OsteoSight Hip
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for OsteoSight Hip.



